Eisenmenger Quality Enhancement Research Initiative (ES-QuERI)

January 22, 2019 updated by: Actelion
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment. Patient data will be collected prospectively for three years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process.

Study Overview

Detailed Description

Approximately 200 male and female adult patients with a history of Eisenmenger will be recruited from approximately 50 cardiology practices over a period of 18 months and will be followed up every six months for the period of three years. Consecutive patients in each practice meeting inclusion and exclusion criteria should be considered for the study. Participating sites will be asked to maintain a screening log to identify which inclusion or exclusion criteria was not met thus excluding them from the study.

Study Type

Observational

Enrollment (Actual)

193

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Arkansas
      • Little Rock, Arkansas, United States, 72202
        • The University of Arkansas for Medical Sciences
    • California
      • Los Angeles, California, United States, 90033
        • University of Southern California Adult Congenital Heart Disease Care Program
      • Los Angeles, California, United States, 90095
        • Ahmanson / UCLA Adult Congenital Heart Disease Center
      • Oakland, California, United States, 94609
        • Berkeley Cardiovascular Medical Group
      • Palo Alto, California, United States, 94303
        • Lucile Packard Children's Hospital
      • San Francisco, California, United States, 94115
        • Centre for Adult Congenital Heart Disease at California Pacific
      • San Francisco, California, United States, 94143-0214
        • University of California, San Francisco
      • Torrance, California, United States, 90502
        • Harbor - UCLA Medical Center - Adult Congenital Heart Disease Program - Division of Cardiology
    • Colorado
      • Aurora, Colorado, United States, 80045
        • University of Colorado Hospital
    • Connecticut
      • New Haven, Connecticut, United States, 06510
        • Yale School of Medicine - Adult Congenital Heart Disease Program
    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • Children's National Medical Center and Washington Hospital Center
    • Illinois
      • Chicago, Illinois, United States, 60612
        • Rush University Medical Center
      • Chicago, Illinois, United States, 60637
        • University of Chicago
    • Kansas
      • Kansas City, Kansas, United States, 66160
        • The University of Kansas Hospital
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • University of Louisville, Pediatric Cardiology
    • Maine
      • Portland, Maine, United States, 04102
        • Pediatric Cardiology Associates
    • Maryland
      • Baltimore, Maryland, United States, 21201
        • University of Maryland School of Medicine
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Children's Hospital Boston and Brigham and Women's Hospital
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan
    • Minnesota
      • Minneapolis, Minnesota, United States, 55455
        • University of Minnesota Physicians Heart Fairview
    • Missouri
      • Kansas City, Missouri, United States, 64111
        • Mid-America Heart Institute / Saint Luke's Hospital / Saint Luke's Cardiovascular Consultants
      • Saint Louis, Missouri, United States, 63110
        • Barnes-Jewish Hospital/St. Louis Children's Hospital / Washington University School of Medicine
    • Nevada
      • Las Vegas, Nevada, United States, 89109
        • Children's Heart Center Nevada
    • New York
      • Bronx, New York, United States, 10467
        • Montefiore Medical Center - Moses Division;The University Hospital for Albert Einstein College of Medicine
      • Cooperstown, New York, United States, 13326
        • Bassett Healthcare Network - Bassett Medical Center
      • New Hyde Park, New York, United States, 11040
        • Cohen's Children's Medical Center of New York - Adult Congenital Heart Disease Program
      • New York, New York, United States, 10029
        • Mount Sinai Medical Center
      • New York, New York, United States, 10075
        • Lenox Hill Hospital
      • New York, New York, United States, 10032
        • Columbia University Pulmonary Hypertension Center
    • North Carolina
      • Asheville, North Carolina, United States, 28803
        • Asheville Cardiology Associates
      • Charleston, North Carolina, United States, 29425
        • Medical University of South Carolina
      • Durham, North Carolina, United States, 27710
        • Duke University Medical Center
      • Greenville, North Carolina, United States, 27834
        • East Carolina University
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cincinnati, Ohio, United States, 45219
        • UC Health/University of Cincinnati
      • Cleveland, Ohio, United States, 44195
        • The Cleveland Clinic Adult Congenital Heart Disease Center
      • Columbus, Ohio, United States, 43210
        • Ohio State University Medical Center
      • Columbus, Ohio, United States, 43215
        • The Research Institute at Nationwide Children's Hospital
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health and Sciences University
    • Pennsylvania
      • Hershey, Pennsylvania, United States, 17033
        • The Pennsylvania State University College of Medicine and The Pennsylvania State Milton S. Hershey Medical Center
      • Philadelphia, Pennsylvania, United States, 19140
        • Temple University Hospital
    • Tennessee
      • Memphis, Tennessee, United States, 38103
        • Methodist Lebonheur Healthcare, UT Lebonheur Pediatric Specialists
      • Nashville, Tennessee, United States, 37232
        • Vanderbilt University Medical Center
    • Texas
      • Houston, Texas, United States, 77005
        • Texas Children's Hospital/Baylor College of Medicine
    • Vermont
      • Burlington, Vermont, United States, 05401
        • Fletcher Allen Health Care
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • University of Virginia Health Systems
      • Lynchburg, Virginia, United States, 24501
        • The Cardiovascular Group Centra
      • Norfolk, Virginia, United States, 23507
        • Children's Specialty Group PLLC, Children's Hospital of the King's Daughters
    • Washington
      • Seattle, Washington, United States, 98105
        • University of Washington
      • Spokane, Washington, United States, 99204
        • Providence Sacred Heart Medical Center and Children's Hospital
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Children's Hospital of Wisconsin, Medical College of Wisconsin Adult Congenital Heart Disease Program

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

200 adult patients with Eisenmenger Syndrome recruited from approximately 50 US cardiology practices.

Description

Inclusion Criteria:

  • Male and female patients
  • Diagnosis of Eisenmenger syndrome based on right heart catheterization data
  • Right to Left intra-cardiac shunting
  • PAH
  • Need for comprehensive management according to guidelines and peer-reviewed evidence
  • Ability and desire to execute the consent for follow up

Exclusion Criteria:

  • Poor mental function, drug, or substance (e.g.,alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study
  • Prior inclusion in this program

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
diagnosis of Eisenmenger Syndrome
subjects with diagnosis of Eisenmenger Syndrome
  1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine
  2. Contraception counseling, and recommendations regarding avoidance of pregnancy
  3. Documentation and prescription of the specific medications:

    1. Oxygen
    2. Diuretic
    3. ASA, Anticoagulant
    4. CCB, BB, ACEI, ARB
    5. Iron Supplementation
    6. Allopurinol
    7. PAH specific therapy
Other Names:
  • management of Eisenmenger Syndrome

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characterization of the clinical course of patients with Eisenmenger Syndrome
Time Frame: up to 3 years
The management of Eisenmenger Syndrome patients over the three year registry period will be compared with established national guidelines. In addition, The Minnesota Living with Heart Failure questionnaire (MLHFQ) will be collected.
up to 3 years

Secondary Outcome Measures

Outcome Measure
Time Frame
Characterization of the demographics of patients with Eisenmenger Syndrome
Time Frame: baseline (visit 1) thru end of study (3 years)
baseline (visit 1) thru end of study (3 years)
Identification of clinical predictors of short-term and long-term outcomes of patients with Eisenmenger Syndrome.
Time Frame: baseline (visit 1) thru end of study (3 years)
baseline (visit 1) thru end of study (3 years)
Characterization of patients treated with PAH-specific medications to patients untreated with PAH-specific medications.
Time Frame: baseline (visit 1) thru end of study (3 years)
baseline (visit 1) thru end of study (3 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Michael Landzberg, MD, Harvard Medical School / Boston Adult Congenital Heart
  • Study Director: Gary Palmer, MD, MBA, Actelion Pharmaceuticals U.S., Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2012

Primary Completion (Actual)

April 17, 2018

Study Completion (Actual)

April 17, 2018

Study Registration Dates

First Submitted

May 9, 2012

First Submitted That Met QC Criteria

June 19, 2012

First Posted (Estimate)

June 20, 2012

Study Record Updates

Last Update Posted (Actual)

January 23, 2019

Last Update Submitted That Met QC Criteria

January 22, 2019

Last Verified

January 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pulmonary Arterial Hypertension

Clinical Trials on Subjects with diagnosis of Eisenmenger Syndrome

3
Subscribe